[HTML][HTML] Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management

E Sechi, L Cacciaguerra, JJ Chen, S Mariotto… - Frontiers in …, 2022 - frontiersin.org
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is the
most recently defined inflammatory demyelinating disease of the central nervous system …

[HTML][HTML] Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis

N Borisow, M Mori, S Kuwabara, M Scheel… - Frontiers in …, 2018 - frontiersin.org
Neuromyelitis optica spectrum disorders (NMOSD) are autoantibody mediated chronic
inflammatory diseases. Serum antibodies (Abs) against the aquaporin-4 water channel lead …

Sex differences in autoimmune disorders of the central nervous system

SM Gold, A Willing, F Leypoldt, F Paul… - Seminars in …, 2019 - Springer
Stronger adaptive immune responses in females can be observed in different mammals,
resulting in better control of infections compared to males. However, this presumably …

Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis

SL Hauser, A Bar-Or, MS Weber, H Kletzl… - Neurology …, 2023 - AAN Enterprises
Background and Objectives Ocrelizumab improved clinical and MRI measures of disease
activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses …

Autoantibodies against central nervous system antigens in a subset of B cell–dominant multiple sclerosis patients

S Kuerten, TV Lanz, N Lingampalli… - Proceedings of the …, 2020 - National Acad Sciences
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system
(CNS), with characteristic inflammatory lesions and demyelination. The clinical benefit of cell …

[HTML][HTML] Antibody therapies in autoimmune encephalitis

I Smets, MJ Titulaer - Neurotherapeutics, 2022 - Springer
Autoimmune encephalitis (AE) comprises a heterogeneous group of disorders in which the
host immune system targets self-antigens expressed in the central nervous system. The …

Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study

BI Yamout, NK El-Ayoubi, J Nicolas… - Journal of …, 2018 - Wiley Online Library
Objective. To evaluate the efficacy and safety of rituximab in multiple sclerosis in a clinical
practice setting. Methods. Clinical data for all adult patients with multiple sclerosis (MS) …

[HTML][HTML] Exit strategies in natalizumab-treated RRMS at high risk of progressive multifocal leukoencephalopathy: a multicentre comparison study

A Zanghì, A Gallo, C Avolio, R Capuano, M Lucchini… - …, 2021 - Springer
The main aim of the study is to evaluate the efficacy and safety profile of ocrelizumab (OCR),
rituximab (RTX), and cladribine (CLA), employed as natalizumab (NTZ) exit strategies in …

Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis

N Capasso, A Nozzolillo, G Scalia, R Lanzillo… - Multiple Sclerosis and …, 2021 - Elsevier
Background We aim to directly compare changes in lymphocyte subpopulations between
chimeric (rituximab) and humanised (ocrelizumab) anti-CD20 antibodies in multiple …

[HTML][HTML] Treatment and relapse prevention of typical and atypical optic neuritis

G Saitakis, BK Chwalisz - International Journal of Molecular Sciences, 2022 - mdpi.com
Optic neuritis (ON) is an inflammatory condition involving the optic nerve. Several important
typical and atypical ON variants are now recognized. Typical ON has a more favorable …